Qlucore (QCORE) Q2 2025 earnings summary

Executive summary

• Net sales for Q2 2024 were SEK 1,855k, down 36% year-over-year, and SEK 3,530k for the first half, down 44% year-over-year.

• Operating result (EBIT) for Q2 was SEK -6,007k and SEK -13,627k for the first half, reflecting increased losses.

• Two key regulatory milestones achieved: technical documentation approved and quality system deviations resolved, paving the way for CE marking and clinical launch in February 2025.

• New version of Qlucore Omics Explorer launched in November, enhancing data analysis capabilities.

Financial highlights

• Q2 net sales: SEK 1,855k (Q2 2023: SEK 2,890k); H1 net sales: SEK 3,530k (H1 2023: SEK 6,317k).

• Q2 EBIT: SEK -6,007k (Q2 2023: SEK -3,409k); H1 EBIT: SEK -13,627k (H1 2023: SEK -8,821k).

• Q2 net result: SEK -5,951k (Q2 2023: SEK -3,256k); H1 net result: SEK -13,480k (H1 2023: SEK -8,255k).

• Cash flow from operating activities in Q2: SEK -6,145k (Q2 2023: SEK -4,143k); H1: SEK -3,665k (H1 2023: SEK -10,013k).

• Cash and cash equivalents at period end: SEK 18,889k (Q2 2023: SEK 45,591k).

Outlook and guidance

• Clinical sales launch for Qlucore Diagnostics expected in February 2025, pending final CE marking.

• No formal market or earnings forecast provided.